Answers are grounded in this paper and cite their sources.
Cell differentiation is determined by a certain set of transcription factors such as MyoD in myogenesis. However, transcription factors that play a positive role in phenotypic gene expression in skeletal cells are largely unknown, except the recently identified CBFA1. Scleraxis is a helix-loop-helix-type transcription factor whose transcripts are expressed in sclerotome and in a certain set of skeletal cells; however, nothing is known about its function with regard to the regulation of cell function. To examine possible roles of scleraxis, we overexpressed scleraxis in osteoblastic ROS17/2.8 cells, which express low levels of scleraxis. Scleraxis overexpression enhanced expression of the aggrecan gene, which is not normally expressed at high levels in these osteoblastic cells. Overexpression of scleraxis also increased mRNA levels of type II collagen and osteopontin while suppressing expression of osteoblast phenotype-related genes encoding type I collagen and alkaline phosphatase. Transient transfection experiments indicated that scleraxis enhanced the chloramphenicol acetyltransferase activity of the reporter construct AgCAT-8, which contained an 8-kilobase pair (kb) fragment of the aggrecan gene including both the promoter and its first intron. Deletion analysis identified a 1-kb region that is responsive to scleraxis within the aggrecan gene. This region contains two adjacent E-box sequences. A 29-base pair DNA fragment (AgE) containing these E-box sequences bound to proteins in the ROS17/2.8 cell nuclear extracts as well as to in vitro translated scleraxis. This binding was competed with unlabeled AgE, but not with a mutated E-box DNA sequence (mAgE), indicating the specificity of the binding activity. The AgE binding activity in the ROS17/2.8 cell nuclear extracts was enhanced in the cells overexpressing scleraxis and was supershifted by the antiserum raised against scleraxis. Furthermore, AgE, but not mAgE, conferred responsiveness to scleraxis overexpression to a heterologous promoter. Finally, replacement mutation of the AgE sequence within the 2.5-kb AgCAT-1 construct significantly reduced its responsiveness to scleraxis. These results indicate that overexpression of a single helix-loop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression via binding to the E-box-containing AgE sequence in ROS17/2.8 cells. Cell differentiation is determined by a certain set of transcription factors such as MyoD in myogenesis. However, transcription factors that play a positive role in phenotypic gene expression in skeletal cells are largely unknown, except the recently identified CBFA1. Scleraxis is a helix-loop-helix-type transcription factor whose transcripts are expressed in sclerotome and in a certain set of skeletal cells; however, nothing is known about its function with regard to the regulation of cell function. To examine possible roles of scleraxis, we overexpressed scleraxis in osteoblastic ROS17/2.8 cells, which express low levels of scleraxis. Scleraxis overexpression enhanced expression of the aggrecan gene, which is not normally expressed at high levels in these osteoblastic cells. Overexpression of scleraxis also increased mRNA levels of type II collagen and osteopontin while suppressing expression of osteoblast phenotype-related genes encoding type I collagen and alkaline phosphatase. Transient transfection experiments indicated that scleraxis enhanced the chloramphenicol acetyltransferase activity of the reporter construct AgCAT-8, which contained an 8-kilobase pair (kb) fragment of the aggrecan gene including both the promoter and its first intron. Deletion analysis identified a 1-kb region that is responsive to scleraxis within the aggrecan gene. This region contains two adjacent E-box sequences. A 29-base pair DNA fragment (AgE) containing these E-box sequences bound to proteins in the ROS17/2.8 cell nuclear extracts as well as to in vitro translated scleraxis. This binding was competed with unlabeled AgE, but not with a mutated E-box DNA sequence (mAgE), indicating the specificity of the binding activity. The AgE binding activity in the ROS17/2.8 cell nuclear extracts was enhanced in the cells overexpressing scleraxis and was supershifted by the antiserum raised against scleraxis. Furthermore, AgE, but not mAgE, conferred responsiveness to scleraxis overexpression to a heterologous promoter. Finally, replacement mutation of the AgE sequence within the 2.5-kb AgCAT-1 construct significantly reduced its responsiveness to scleraxis. These results indicate that overexpression of a single helix-loop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression via binding to the E-box-containing AgE sequence in ROS17/2.8 cells. Determination of specific cell fate is under the control of a certain set of various types of transcription factors. Among these, the basic helix-loop-helix (bHLH) 1The abbreviations used are: bHLH, basic helix-loop-helix; FBS, fetal bovine serum; kb, kilobase pair(s); GAPDH, glyceraldehyde-6-phosphate dehydrogenase; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay. 1The abbreviations used are: bHLH, basic helix-loop-helix; FBS, fetal bovine serum; kb, kilobase pair(s); GAPDH, glyceraldehyde-6-phosphate dehydrogenase; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay.-type transcription factor family is well known for its critical role in the transcriptional regulation of cellular differentiation in myogenesis, hematopoiesis, and neurogenesis (1Olson E.N. Genes Dev. 1990; 4: 1454-1461Crossref PubMed Scopus (553) Google Scholar, 2Olson E.N. Mol. Endocrinol. 1993; 7: 1369-1378Crossref PubMed Scopus (60) Google Scholar, 3Weintraub H. Cell. 1993; 75: 1241-1244Abstract Full Text PDF PubMed Scopus (928) Google Scholar, 4Jan Y.N. Jan L.Y. Cell. 1993; 75: 827-830Abstract Full Text PDF PubMed Scopus (392) Google Scholar). In this machinery, tissue-specific gene transcription is positively regulated by formation of heterodimers between tissue-specific bHLH proteins and ubiquitous bHLH proteins such as E12/E47 (5Murre C. McCaw P.S. Baltimore D. Cell. 1989; 56: 777-783Abstract Full Text PDF PubMed Scopus (1846) Google Scholar), whereas it is negatively regulated by another type of regulatory HLH protein lacking the basic DNA-binding domain, such as Id (6Benezra R. Davis R.L. Lockshon D. Turner D.L. Weintraub H. Cell. 1990; 61: 49-59Abstract Full Text PDF PubMed Scopus (1797) Google Scholar). These heterodimers interact withcis-acting elements (CANNTG) called E-boxes, which are located in the promoter/enhancer regions of tissue-specific genes (1Olson E.N. Genes Dev. 1990; 4: 1454-1461Crossref PubMed Scopus (553) Google Scholar, 2Olson E.N. Mol. Endocrinol. 1993; 7: 1369-1378Crossref PubMed Scopus (60) Google Scholar, 3Weintraub H. Cell. 1993; 75: 1241-1244Abstract Full Text PDF PubMed Scopus (928) Google Scholar, 4Jan Y.N. Jan L.Y. Cell. 1993; 75: 827-830Abstract Full Text PDF PubMed Scopus (392) Google Scholar, 7Tamura M. Noda M. J. Cell Biol. 1994; 126: 773-783Crossref PubMed Scopus (80) Google Scholar). Although no skeletal tissue-specific HLH transcription factors have yet been identified, E-box sites are present in the promoters of the genes encoding osteocalcin (7Tamura M. Noda M. J. Cell Biol. 1994; 126: 773-783Crossref PubMed Scopus (80) Google Scholar), osteopontin, 2M. Noda, unpublished observation. 2M. Noda, unpublished observation. and alkaline phosphatase,2 which are the markers of osteoblastic differentiation (9Rodan G.A. Noda M. Crit. Rev. Eukaryotic Gene Expression. 1991; 1: 85-98PubMed Google Scholar, 10Siddhanti S. Quarles D. J. Cell. Biochem. 1994; 55: 310-320Crossref PubMed Scopus (78) Google Scholar). Previously, we reported that osteoblasts express ubiquitous type HLH transcription factors and that expression of such HLH transcription factors is under the control of calciotropic hormones and cytokines (7Tamura M. Noda M. J. Cell Biol. 1994; 126: 773-783Crossref PubMed Scopus (80) Google Scholar, 11Kawaguchi N. Deluca H.F. Noda M. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 4569-4572Crossref PubMed Scopus (56) Google Scholar). Scleraxis has recently been identified as a basic helix-loop-helix transcription factor (12Cserjesi P. Brown D. Ligon K. Lyons G. Olson E.N. Development (Camb.). 1995; 121: 1099-1110Crossref PubMed Google Scholar). Its mRNA is expressed in mouse embryos between days 9.5 and 10.5 post-coitum in sclerotomes and in mesenchymal cells of the body wall and limb buds. Subsequently, scleraxis is expressed at high levels within mesenchymal precursors of the axial and appendicular skeletons and in cranial mesenchyme in advance of chondrogenesis (12Cserjesi P. Brown D. Ligon K. Lyons G. Olson E.N. Development (Camb.). 1995; 121: 1099-1110Crossref PubMed Google Scholar). Scleraxis is also expressed in osteoblastic osteosarcoma ROS17/2.8 cells, although at low levels, and its expression is regulated by transforming growth factor-β, which has been implicated in bone formation (13Liu Y Cserjesi P. Nifuji A. Olson E.N. Noda M. J. Endocrinol. 1996; 151: 491-499Crossref PubMed Scopus (20) Google Scholar). However, nothing was known about its functional role in the regulation of cell fate. To explore the roles of scleraxis in the regulation of skeletal cell functions, we overexpressed scleraxis in osteoblastic ROS17/2.8 cells by establishing stably transfected cell lines. We found that scleraxis enhanced expression of the aggrecan gene and suppressed expression of the type I collagen and alkaline phosphatase genes in these osteoblastic ROS17/2.8 cells. Analysis of the aggrecan promoter showed that scleraxis enhanced aggrecan gene transcription via its E-box-containing sequence (AgE). These data suggest that scleraxis could be one of the key regulatory transcription factors that are involved in the positive regulation of genes encoding proteins of chondrogenic phenotype. ROS17/2.8 cells were provided by Dr. Gideon Rodan (Merck Research Laboratories) and were maintained in modified F-12 medium supplemented with 5% fetal bovine serum (FBS) (14Noda M. Rodan G.A. J. Cell Biol. 1989; 108: 713-718Crossref PubMed Scopus (110) Google Scholar). All cultures were fed with fresh medium every 2–3 days. Stable transfections were carried out by employing the calcium phosphate precipitation technique as described by Parker and Stark (15Parker B.A. Stark G.R. J. Virol. 1979; 31: 360-369Crossref PubMed Google Scholar). Approximately 5 × 105 cells were cotransfected with 10 μg of expression vector plasmid containing scleraxis cDNA and 0.5 μg of neo expression vector. Other sets of cells were transfected with the neo vector alone. After a 4-h incubation, the cells were treated with 15% glycerol for 30 s. Approximately 24 h later, the cells were trypsinized, replated at 6 × 104 cells in a 56-cm2 dish, and fed with modified F-12 medium containing 200 μg/ml G418 (Life Technologies, Inc.) as described (16Davies J. Jimenez A. Am. J. Trop. Med. Hyg. 1980; 29: 1089-1092Crossref PubMed Scopus (72) Google Scholar). The medium was supplemented with 5% FBS. After 1 month of culture, individual clones were isolated. RNA was extracted and subjected to Northern blot analysis. Total RNA was extracted according to the acid guanidium thiocyanate/phenol/chloroform method (17Chomczynski P. Sacchi N. Anal. Biochem. 1987; 162: 156-159Crossref PubMed Scopus (63084) Google Scholar). Total cellular RNA was subjected to Northern analysis by fractionation on 1.0% agarose gels containing 0.66 mformaldehyde. The RNAs were transferred to nylon filters (Hybond-N, Amersham Corp.) by electroblotting for 18 h (18Thomas P. Proc. Natl. Acad. Sci. U. S. A. 1980; 77: 5201-5205Crossref PubMed Scopus (5857) Google Scholar). A 1.2-kb scleraxis cDNA probe was labeled with [α-32P]dCTP (New Life Science Products) using random primers and the Klenow fragment (Pharmacia, Uppsala, Sweden) (19Feinberg A.P. Vogelstein B. Anal. Biochem. 1983; 132: 6-13Crossref PubMed Scopus (16646) Google Scholar). Complementary DNAs for osteopontin and alkaline phosphatase were gifts from Dr. Gideon Rodan; α1(I) collagen cDNA was provided by Dr. Barbara Kream (University of Connecticut); and glyceraldehyde-6-phosphate dehydrogenase (GAPDH) was provided by Dr. Sevgi Rodan. Filters were hybridized to the probes overnight at 42 °C in hybridization solution containing 50% formaldehyde, 5 × SSC (1 × SSC = 0.15 mNaCl and 10 mm sodium citrate), 5 × Denhardt's solution, 0.1% SDS, and 50 mg/ml sheared and denatured herring sperm DNA. Membranes were washed at 65 °C in 0.2 × SSC and 0.1% SDS and exposed to x-ray films at −70 °C using intensifying screens. Transfection of plasmid DNA into ROS17/2.8 cells was performed using DNA-lipid complexes (20Felgner P.L. Gadek T.R. Holm M. Roman R. Roman H. Roman W. Wenz M. Northrop J.P. Ringold G.M. Danielsen M. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 7413-7417Crossref PubMed Scopus (4334) Google Scholar). The cells were cotransfected with 1 μg of scleraxis expression vector (12Cserjesi P. Brown D. Ligon K. Lyons G. Olson E.N. Development (Camb.). 1995; 121: 1099-1110Crossref PubMed Google Scholar) and 1 μg of aggrecan reporter plasmids (AgCAT-8, AgCAT-1, or AgCAT-6 containing a or 1-kb fragment of the 1 the 1 of the mouse aggrecan gene, H. S. K. K. Biochem. J. 1995; PubMed Scopus Google Scholar). The scleraxis expression vector was also cotransfected with or which were by a 29-base pair to a region as from to into the of the promoter plasmid The contained two or two mutated used as a control C. DNA a Scholar). construct was by a replacement mutation in the of the 2.5-kb aggrecan promoter according to the method described W. Anal. Biochem. 1992; PubMed Scopus Google Scholar). The cells were exposed to the DNA solution for h and in fresh F-12 medium supplemented with 5% FBS. After the cell extracts were for analysis of activity. of cellular proteins were in the mm and overnight at The of was by by of the of was performed with a RNA was in a for 1 h at °C with a of 1 μg of DNA and (Life Technologies, Inc.) and in the of The RNA was and and The was in of In vitro of the RNA was with a Corp.) in a were at 30 °C for 1 h in the or of was by of the DNA binding we in vitro translated proteins as described extracts were according to the method described by 1983; PubMed Scopus Google Scholar) from ROS17/2.8 cells and cells. a 29-base pair to the sequence (AgE) from to containing the was A was to of the by The AgE sequence of the of this was as and with E-box These were to the AgE sequence probe and labeled by a at using [α-32P]dCTP and the Klenow was by the probes of of the probe were with μg of nuclear protein for at 30 °C in a containing mm mm 0.2 mm 0.5 5 μg of bovine serum and μg of a of unlabeled probes was in the binding The were the unlabeled AgE sequence as described or the mutated AgE sequence as We also used scleraxis E-box and mutated as the containing an E-box sequence with the E-box was reported (12Cserjesi P. Brown D. Ligon K. Lyons G. Olson E.N. Development (Camb.). 1995; 121: 1099-1110Crossref PubMed Google Scholar) to be bound by scleraxis. the the E-box was mutated to to These used as were with the nuclear extracts for the of the The complexes were on a as described (7Tamura M. Noda M. J. Cell Biol. 1994; 126: 773-783Crossref PubMed Scopus (80) Google Scholar). the of or antiserum raised against scleraxis were to the and for To examine functional roles of scleraxis in the regulation of skeletal cell we transfected a scleraxis expression vector into types of cell lines. cells are known to be and to types of mesenchymal cells, we first scleraxis transfection into these cells. However, we not in expression of genes to skeletal we found that scleraxis is expressed in the osteoblastic cell although at low levels, we to scleraxis in these cells. We cell by a scleraxis expression vector and a neo expression vector into ROS17/2.8 cells. clones and were isolated. Northern analysis of the RNA from these cells is in Scleraxis overexpression in the transfected cells was by the increased levels of the scleraxis mRNA in the and clones To scleraxis overexpression in the cells enhanced expression of encoding markers in the and clones with control ROS17/2.8 cells mRNA expression was enhanced in the scleraxis type II collagen mRNA was expressed at a low in control ROS17/2.8 cells and scleraxis overexpression also enhanced type II collagen mRNA expression II Furthermore, the enhanced expression of phenotype-related genes was by the of the mRNA levels of type I collagen and alkaline phosphatase I and These data that scleraxis in expression of skeletal phenotype-related Scleraxis overexpression also enhanced mRNA expression of osteopontin, which has been known to be expressed both in osteoblasts and Overexpression of scleraxis not levels in these clones with control ROS17/2.8 cells, indicating the specificity of the scleraxis The levels of expression of the genes in the control ROS17/2.8 cells were to of the ROS17/2.8 cells not To examine scleraxis the transcriptional activity of the aggrecan gene, a reporter gene construct containing an fragment of the mouse aggrecan gene including the the first and a of the first H. S. K. K. Biochem. J. 1995; PubMed Scopus Google Scholar) was cotransfected with the scleraxis expression vector into ROS17/2.8 cells. Scleraxis overexpression enhanced the transcriptional activity of the construct and To region of the aggrecan gene to scleraxis we also the of the two AgCAT-1 and AgCAT-6 (1 The of these were also enhanced by with the scleraxis expression vector 5 and 6 and and and 10 and the scleraxis overexpression not the activity of the control indicating the specificity of the of scleraxis on the aggrecan promoter 1 and the 1-kb aggrecan gene we identified a 29-base pair which we as AgE containing two E-box sequences at to To examine AgE is the of scleraxis, we using AgE as a in AgE bound the proteins in nuclear extracts from ROS17/2.8 cells in the This binding was competed with the of a of unlabeled AgE but not with which contains in the E-box sequences indicating the specificity of the binding activity. The binding activity was also competed with a of the sequence which is another E-box sequence known to scleraxis (12Cserjesi P. Brown D. Ligon K. Lyons G. Olson E.N. Development (Camb.). 1995; 121: 1099-1110Crossref PubMed Google Scholar), but it was not competed with the which contains in the E-box to This is with that scleraxis is expressed in these cells, although at a low (13Liu Y Cserjesi P. Nifuji A. Olson E.N. Noda M. J. Endocrinol. 1996; 151: 491-499Crossref PubMed Scopus (20) Google Scholar). This was supershifted the antiserum raised against scleraxis was to the which was for not the and the supershifted was competed with the of an of unlabeled AgE To examine the AgE sequence scleraxis, scleraxis protein was in vitro and subjected to in AgE bound scleraxis protein and this was competed with AgE or and but not with or and against but not supershifted the 6 and and the supershifted was also competed with AgE the in was by the protein and analysis on which showed two and the of the was which is the of scleraxis to in AgE binding to nuclear proteins was increased in the nuclear from ROS17/2.8 cells with the control cells Furthermore, an mobility was in cells The of the antiserum against scleraxis supershifted these to the one mobility and binding activity is enhanced in the nuclear from cells. were performed as described under and The AgE sequence to the region of the aggrecan gene from to containing two and was as a and used as a AgE probe nuclear from ROS17/2.8 cells and nuclear from cells In antiserum against scleraxis was to the The indicate specific and the the supershifted We the AgE sequence is the that is for the scleraxis of To AgE and were in of the heterologous promoter to two and 6 construct was cotransfected into ROS17/2.8 cells with the scleraxis expression vector or as a in 1 and scleraxis enhanced the transcriptional activity of This scleraxis was no and the scleraxis expression vector were cotransfected 6 5 and 6 and The transcriptional activity of in these cells was not by with the scleraxis expression vector and 10 indicating the specificity of the scleraxis on the E-box-containing sequence (AgE) in the aggrecan gene. To that the AgE sequence is critical to regulation in the of the aggrecan gene, we into AgE in which contains a 2.5-kb fragment of the aggrecan gene. This 2.5-kb aggrecan gene fragment with a mutation in AgE was in of to in 5 and 6 and scleraxis overexpression enhanced AgCAT-1 whereas the of scleraxis overexpression was significantly reduced by a mutation in AgE in the of the 2.5-kb These data indicate that the AgE sequence is the scleraxis in the aggrecan gene. This for the first that overexpression of a single type transcription factor expression of the aggrecan gene in osteoblastic osteosarcoma ROS17/2.8 cells. of the helix-loop-helix-type transcription factor family have been implicated in differentiation of cells or cells (1Olson E.N. Genes Dev. 1990; 4: 1454-1461Crossref PubMed Scopus (553) Google Scholar, 2Olson E.N. Mol. Endocrinol. 1993; 7: 1369-1378Crossref PubMed Scopus (60) Google Scholar, 3Weintraub H. Cell. 1993; 75: 1241-1244Abstract Full Text PDF PubMed Scopus (928) Google Scholar, 4Jan Y.N. Jan L.Y. Cell. 1993; 75: 827-830Abstract Full Text PDF PubMed Scopus (392) Google Scholar). However, nothing has been implicated in the positive regulation of the of skeletal tissue-specific gene expression except the recently identified which a role in osteoblast differentiation P. R. G. Cell. 89: Full Text Full Text PDF PubMed Scopus Google Scholar, H. S. A. K. K. M. M. R. S. Cell. 89: Full Text Full Text PDF PubMed Scopus Google Scholar, A.P. A. S. Cell. 89: Full Text Full Text PDF PubMed Scopus Google Scholar). This scleraxis, a recently of the helix-loop-helix-type transcription factor as a of gene In for we also found that scleraxis is expressed at a high in such as which express the aggrecan and type II collagen Overexpression of scleraxis enhanced expression of at two genes encoding aggrecan and type II Furthermore, analysis of the aggrecan gene showed that the scleraxis was by an analysis of the fragment identified that a 29-base pair region (AgE) located from to which contains two adjacent E-box sequences to is for the scleraxis binding and of aggrecan promoter activity. These results indicate that the aggrecan gene is a of scleraxis and that scleraxis its via binding to E-box sequences in the aggrecan gene. of mesenchymal cells into is by expression of markers specific to M. P. J. Cell Biol. 1989; 108: PubMed Scopus Google Scholar). In the to examine scleraxis we overexpressed scleraxis in cells, but these experiments to in expression of skeletal tissue-specific genes in these we ROS17/2.8 cells, as we reported (13Liu Y Cserjesi P. Nifuji A. Olson E.N. Noda M. J. Endocrinol. 1996; 151: 491-499Crossref PubMed Scopus (20) Google Scholar), expressed low levels of scleraxis. In ROS17/2.8 cells, the of scleraxis overexpression is in the of aggrecan gene In the type II collagen mRNA is also We have and in of the aggrecan mRNA levels were but mRNA levels were not not on these we that scleraxis as a regulatory transcription factor for expression of although of genes is a certain in the levels of by scleraxis on the aggrecan gene and on the type II collagen gene. The for this are not at this The of scleraxis on expression of the aggrecan and type II collagen genes to be specific to this bHLH transcription factor we not such in overexpression of another but bHLH transcription factor, R. Cserjesi P. Ligon K. Olson E.N. Dev. Biol. 1995; PubMed Scopus Google Scholar), which as as in or ROS17/2.8 cells. mRNA was in these is also to the scleraxis could the aggrecan gene in ROS17/2.8 cells, but not in cells. scleraxis not gene expression in cells, it is that scleraxis as a transcription factor, with a on aggrecan gene of osteoblastic cells is the of the osteoblast of type I collagen and alkaline phosphatase mRNA expression mRNA expression was suppressed in one but was not in the not expression is enhanced by scleraxis in ROS17/2.8 cells. however, known that osteopontin is expressed in both and bone J. 1993; 7: PubMed Scopus Google Scholar). and are known in differentiation factors such as MyoD and (1Olson E.N. Genes Dev. 1990; 4: 1454-1461Crossref PubMed Scopus (553) Google Scholar, 2Olson E.N. Mol. Endocrinol. 1993; 7: 1369-1378Crossref PubMed Scopus (60) Google Scholar, 3Weintraub H. Cell. 1993; 75: 1241-1244Abstract Full Text PDF PubMed Scopus (928) Google Scholar) in the of In this MyoD enhances gene expression and at the to these scleraxis could have a one is to expression of chondrogenic and the is to that of helix-loop-helix-type transcription factors are known to elements in the promoter regions of and heterodimers have been reported to to the E-box sequence with a for the two as or The AgE region in the first of the aggrecan gene contains two by at and The two in these are and This could be to that the AgE sequence in vitro translated scleraxis in the of the of two in could also scleraxis binding is that the reported E-box sequence that heterodimers of scleraxis and protein for binding (12Cserjesi P. Brown D. Ligon K. Lyons G. Olson E.N. Development (Camb.). 1995; 121: 1099-1110Crossref PubMed Google Scholar) is not from skeletal tissue-specific This E-box sequence was from the promoter in a gene Cserjesi (12Cserjesi P. Brown D. Ligon K. Lyons G. Olson E.N. Development (Camb.). 1995; 121: 1099-1110Crossref PubMed Google Scholar) not scleraxis genes at that that were known at that the aggrecan gene is the first gene to be identified as a scleraxis AgE sequence is the first E-box for scleraxis These could be the possible for the scleraxis binding to AgE In we found that scleraxis overexpression enhanced aggrecan gene expression in osteoblastic ROS17/2.8 cells while it osteoblastic These the that scleraxis is one of the key regulatory transcription factors in the of chondrogenic
No takes yet. Share an insight, caveat, or question.
Liu et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: